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SYNOPSIS
Injectable and implantable porosified silicon (pSi) carriers and devices for prolonged and
controlled delivery of biotherapeutics offer great promise for treatment of various chronic ailments
and acute conditions. Polyethylene glycols (PEGs) are important surface modifiers currently used
in clinic mostly to avoid uptake of particlulates by reticulo-endothelial system (RES). In this work
we show for the first time that covalent attachment of PEGs to the pSi surface can be used as a
means to finely tune degradation kinetics of silicon structures. Seven PEGs with varying
molecular weights (245, 333, 509, 686, 1214, 3400 and 5000Da) were employed and the
degradation of PEGylated pSi hemispherical microparticles in simulated physiological conditions
was monitored by means of ICP-AES, SEM and fluorimetry. Biocompatibility of the systems with
human macrophages in vitro was also evaluated. The results clearly indicate that controlled
PEGylation of silicon microparticles can offer a sensitive tool to finely tune their degradation
kinetics and that the systems do not induce release of proinflammatory cytokines IL-6 and IL-8 in
THP1 human macrophages.
Keywords
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INTRODUCTION
Porous silicon (pSi) was discovered by Uhlir at Bell Laboratories in the mid 1950s, 1 and is
currently being employed in various fields of biomedical research with diverse applications
including biomolecular screening, 2–3 optical biosensing, 4–5 drug delivery through
injectable carriers 6–7 and implantable devices 8 as well as orally administered medications
with improved bioavailability 9. There are already several FDA approved and marketed
products based on pSi technology which found their niche in ophthalmology 10 and other,
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based on radioactive 32P doped pSi is currently in clinical trials, as a potential new
brachytherapy treatment for inoperable liver cancer 11. This paper presents PEGylation as a
method to control degradation kinetics of porous silicon structures (pSi) with important
biomedical applications, e.g. in controlled drug delivery and osteoregeneration.
Important requirements for injectable drug delivery carriers are (i) biocompatibility, (ii)
efficient clearance or biodegradability, and (iii) favorable biodistribution, for example
avoidance or control of uptake by the reticulo- endothelial system (RES). pSi for drug
delivery applications mainly features drug molecules that are directly loaded within the
matrix of pSi membranes or microcarriers and are trapped within the pores via specific or
non-specific interactions. Drug release is then achieved mainly through pSi degradation over
time. Canham and colleagues 12–13 have reported that the biodegradation rates of pSi
structures can be controlled by the pore size: the larger the pore the faster the degradation
and thus the release of the drug molecule.
More recently, our group 7 proposed to use pSi microparticles (first stage particles), with
pore sizes ranging from 10 to 50 nm, as a multistage and multifunctional delivery systems
where various nano-sized particulates (second stage particles) with different payloads or
functions (therapeutic, imaging, thermal ablation and magnetic guidance agents) can be
loaded simultaneously. In such applications, the pore size is not only playing an important
role in the degradation and release kinetics but it would also significantly affect the loading
efficiency of the second stage nanoparticles. It is thus fundamental to decouple the
dependence of loading, degradation and release, on particles pore size, in order to optimize
the whole system.
Polyethylene glycols (PEGs) represent the major category of surface modifying agents used
in classical drug delivery systems and in pharmaceutical dosage forms, mainly due to
avoidance of RES uptake and thus a possibility to control biodistribution and circulation
time 14. These hydrophilic polymers are approved by FDA for use in food, cosmetics and
pharmaceuticals, including injectable, topical, rectal and nasal formulations. PEG molecules
demonstrate little toxicity, and are cleared from the body, without being metabolized, by
either the kidneys for PEGs < 30 kDa or in the feces for longer PEGs. PEG molecules
generally lack immunogenicity and no production of the antibodies against PEGs was
reported in the literature under regular clinical administration of pegylated proteins 15. We
hypothesized that the degradation of mesoporous silicon based carriers can be regulated not
only by controlling the pores size, but also through surface modifications. In this study we
evaluated the effect of PEGylation of the mesoporous silicon particles on their degradation.
We propose to fine tune the biodegradation kinetics of pSi particles using surface
functionalization with PEGs of various molecular weights. In the present work, the
degradation of pSi hemispherical microparticles was monitored by means of ICP-AES, SEM
and fluorimetry. The biocompatibility of the systems with human macrophages was
evaluated. The results clearly indicate that controlled PEGylation of silicon microparticles
can offer a sensitive tool to tune their degradation kinetics.
MATERIALS AND METHODS
Fabrication, surface modification and characterization of porous silicon particles
Mesoporous silicon microparticles were fabricated by photolithography and electrochemical
etching in the Microelectronics Research Center at The University of Texas at Austin as
previously described [6]. The large pore (LP, 30–40nm pores) silicon particles were formed
in a mixture of hydrofluoric acid (49% HF) and ethanol (3:7 v/v) by applying a current
density of 80 mA cm−2 for 25 s. A high porosity layer was formed by applying a current
density of 320 mA cm−2 for 6 s. For fabrication of small pores (SP, 10nm) silicon particles,
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a solution of HF and ethanol was used with a ratio of 1:1 (v/v), with a current density
applied of 6 mA cm−2 for 1.75 min. After removing the nitride layer by HF, particles were
released by ultrasound in isopropyl alcohol (IPA) for 1 min.
Silicon microparticles in IPA were dried in a glass beaker by heating (80–90 °C) and then
oxidized in a piranha solution (1:2 H2O2:concentrated H2SO4 (v/v), Sigma) at 100–110 °C
for 2 h, with intermittent sonication to disperse the aggregates, washed in DI water and
stored at 4 °C in DI water until further use. Prior to modification with 3-
Aminopropyltriethoxysilane (APTES, Sigma). The particles were then washed with DI
water followed by IPA, suspended in IPA containing APTES (0.5% v/v) for 45 min at room
temperature, washed 5 times with IPA and stored in IPA at 4°C.
APTES modified large pore particles were reacted with 10 mM mPEG-SCM or NHS-m-
dPEG (QuantaBiodesign, USA) in 400–500μL acetonitrile for 1.5 hours. The succinimidyl
ester on the PEGs reacts with an amino group that is exposed on the surface of the APTES
particles giving a stable chemical linkage of PEGs to the particles. The particles were then
washed (by centrifugation) in deionized water 4–6 times to remove any unreacted PEGs.
The particles were stored in deionized water or IPA at 4 °C till further use.
Volumetric particle size, size distribution and count was obtained using a Z2 Coulter®
Particle Counter and Size Analyzer (Beckman Coulter, Fullerton, CA, USA). Prior to the
analysis, the samples were dispersed in the balanced electrolyte solution (ISOTON® II
Diluent, Beckman Coulter Fullerton, CA, USA) and sonicated for 5 seconds to ensure a
homogenous dispersion.
The zeta potential of the silicon particles was analyzed using a Zetasizer nano ZS (Malvern
Instruments Ltd., Southborough, MA, USA). For the analysis, 2 μL particle suspension
containing at least 2×105 particles to give a stable zeta value evaluation were injected into a
sample cell countering filed with phosphate buffer (PB, 1.4 mL, pH 7.3). The cell was
sonicated for 2min, and then an electrode-probe was put into the cell. Measurements were
conducted at room temperature (23°C) in triplicates.
Degradation study in simulated physiological conditions
To evaluate degradation kinetics, 107 of the particles were added to PBS (1.5mL, pH 7.2) or
100% fetal bovine serum (FBS, Hyclone, USA). The samples (n=3) were incubated at 37°C
and constantly mixed using a rotary shaker until the appropriate time points had elapsed.
Aliquots (85μL) were taken from the tubes: 75 μL were filter-spun (0.45 μm filter) to
separate the undegraded particles from the degradation medium and the resulting liquid was
stored at 4°C for later analysis of total silicon by Inductively Coupled Plasma Atomic
Emission Spectrometer (ICP-AES). The remaining 10 μL were extensively washed with DI
water to remove the salts, placed on the grid, dried in a dessicator and further analyzed for
particles morphology by Scanning Electron Microscopy (SEM). In the case of fluorescent
PEG conjugated to the surface of the particles, the samples (150 μL) were spun down at
4500rpm × 20min, the supernatant was collected into 96 wells plates and analyzed for the
quantity of fluorophore released from the particles by fluorimetry and for Si contents by
ICP-AES.
Silicon contents released to from the particles during the degradation process was measured
using a Varian Vista-Pro ICP–AES. Si was detected at 250.69, 251. 43, 251.61 and
288.158nm. A calibration run including the internal control (Yttrium, 1 ppm) was made
before each group of 1wsample (100%), the particles were dissolved in 1N NaOH for 4
hours in 37C. Further, all results were expressed as % of the silicic acid released to the
medium.
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SEM was applied to examine the structure and morphology of the particles. Samples were
sputter-coated with gold for 2 min at 10nm using a CrC-150 Sputtering System (Torr
International, New Windsor, NY) and observed under a FEI Quanta 400 field emission
scanning electron microscope (FEI Company, Hillsboro, OR) at an accelerating voltage of
20 kV, chamber pressure of 0.45 Torr and spot size 5.0.
Fluorescence of the particles conjugated to FITC-PEG (MW 3400) was assessed using a
FACScalibur (Becton Dickinson). Bivariate dot-plots defining logarithmic side scatter
(SSC) versus logarithmic forward scatter (FSC) were used to evaluate the size and shape of
the unlabeled silicon particles (3 μm in diameter, 1.5 μm in height) and to exclude non-
specific events from the analysis. A polygonal region (R1) was defined as an electronic gate
around the centre of the major population of interest for undegraded particles, which
excluded events that were too close to the signal-to-noise ratio limits of the cytometer. The
peaks identified in each of the samples were analyzed in the corresponding fluorescent
histogram and the geometric mean values recorded. For particle detection, the detectors used
were FSC E- 1 and SSC with a voltage setting of 474 volts (V). The fluorescent detector
FL1 was set at 800 V and green fluorescence was detected with FL1 using a 530/30 nm
band-pass filter. For each analysis, 50,000–200,000 gated events were collected. Instrument
calibration was carried out before, in between, and after each series of experiments for data
acquisition using BD Calibrite™ beads (3.5 μm in size).
For the analysis of fluorescence intensity analysis the samples were placed on a 96-well
plate (Nunclon, Denmark) and quantities of FITC-PEG released from the particles surface
were determined in triplicates using BMG FluoSTAR microplate variable wavelength
fluorescence spectrophotometer (Galaxy, excitation 488nm, emission 523 nm).
Based on the observed experimental results, a mathematical model was identified and used
to get further insight into the underlying physical and chemical processes which are involved
in the effect of PEGylation on particles degradation.
Evaluation of biocompatibility of PEGylated particles with human macrophages in vitro
THP-1 monocyte cell line was obtained from the American Type Culture Collection
(Manassas, VA). Cells were cultured at 0.4–2×106 cells/mL in RPMI 1640 containing heat-
inactivated FCS (10 % w/v), glutamine (2 mM), penicillin (100 U/mL), and streptomycin
(100 μg/mL), and maintained at 37 °C under 5 % CO2. All reagents and medium were
purchased from ATCC and Gibco BRL (Gaithersburg, MD). THP-1 cells (0.2×106 cells/
well) were differentiated into macrophages in 24 well plates containing 1 mL medium/well
with phorbol ester (80 ng, PMA, Sigma USA) over 72 h. A stock solution of PMA was
prepared by dissolving PMA in sterile dimethylsulfoxide (Sigma). The stock solution was
stored frozen at −20°C. Immediately prior to use, the PMA stock solution was diluted in
RPMI medium. The differentiation-inducing dose of PMA for THP-1 cells was determined
in preliminary dose-response experiments (data not shown). The criteria for differentiation
of THP-1 cells were cell adherence, changes in cell morphology, and changes in the cell
surface marker expression profile. Following 72 hours incubation, the cells were washed
two times with the medium and incubated with particles (5 particles/cell). The supernatants
were collected and stored at −70 °C until the cytokine analysis. Proinflammatory cytokines,
interleukin-6 (IL-6) and interleukin-8 (IL-8) were analyzed using commercial ELISA kits
(BD Biosciences, USA).
RESULTS AND DISCUSSION
Mesoporous hemispherical silicon microparticles were fabricated by photolithography and
electrochemical etching as previously described 7. In our study, we used standard surface
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modification procedures developed for silicon-based materials (schematically presented in
Figure 1). During the oxidation process, partial erosion of the particle surface led to an
introduction of free hydroxyl groups, imparting to the particles a negative zeta potential
(−31.5mV). Through silane chemistry the hydroxyl surface groups were covalently coupled
to positively charged 3-Aminopropyltriethoxysilane (APTES), reversing the net surface
charge of the particles to +14.73mV. APTES amine groups further served as a background
for linking molecules to the particles surface. First, to estimate the range of molar ratios
suitable for further conjugation of surface modifiers, we evaluated the effect of fluorescent
probe concentration in the reaction medium on the fluorescence of the silicon particles. In
the concentration range of 3.75–15mM of the 488-Dylight in the reaction medium, the net
fluorescence intensity of the particles reached a plateau, which can be attributed to
saturation of the bindings sites on the particles surface (Supplementary data, Figure 1S). A
slight reduction in the fluorescence intensity of the particles was observed at higher
concentrations of the probe, which could be related to the quenching effect of the probe on
the surface. This general behavior was consistent and repetitive among different
experiments, though numerical values of fluorescent intensity slightly vary, due to the
slightly different surface area and properties of pSi microparticles. Based on these results, a
concentration of 10mM of PEG was chosen in order to obtain a saturation of the modifier on
the particle surface. As in the case of the fluorescent probe, PEG molecules (MWs from 245
to 5000) were bound to the particles through APTES amine groups. No direct correlation
was observed between the length of the PEG molecule and the zeta potential values (Table
1), though all PEGs and fluorescent probes bound to APTES amine groups resulted in a
neutralization of the positive charges introduced by APTES thus causing a slightly negative
zeta potential, which could be partially explained by the charge-shielding effect of PEG
backbones.
To evaluate the degradation rate of the particles under the simulated physiological
conditions, we initially tested the degradation of small pores (10nm) and large pores (30–
50nm) non-PEGylated APTES particles in phosphate buffered saline (PBS, pH 7.2) and fetal
bovine serum serum (FBS) (Figure 2). In agreement with the published literature,
degradation kinetics of the mesoporous Si particles was strongly dependant on the pore size
13. Particles having small pores degraded much slower than the particles with large pores.
As the following step, we evaluated the influence of a modification with various PEGs on
the degradation kinetics of the particles. Seven PEGs with varying molecular weights were
employed: 245, 333, 509, 686, 1214, 3400 and 5000Da. Figure 3 shows degradation profiles
of PEGylated particles with 30–50nm pores in PBS and 100% serum in vitro at 37°C.
Generally, particles degraded faster in serum, and the higher was PEG’s molecular weight,
the slower the degradation profile of the particles was obtained in both physiological media.
The conjugation of the PEG with lowest molecular weight to the particles surface did not
induce any change in the degradation kinetics in serum, but inhibited degradation and
consequently the release of orthosilicic acid into buffer. When PEGs with the longer chains
were evaluated, Si mass loss from the particles was slowed down, and the almost fully
degraded within 18 to 24 hours in serum and within 48 hours in PBS. The most dramatic
effect was observed for PEGs 3400 and 5000 which inhibited the degradation of the systems
very prominently, with complete degradation achieved after four days. For these particles
during the early stages of the degradation, there was a “lag” period of little or no mass loss.
The degradation process as a function of time as shown in Figure 3, can be separated into
two phases: phase I, up to about 24 hours; and phase II, from 24 hours onward. The
percentage of Si released (Mt) in solution over time can be described quite accurately in both
phases employing a general power law αtβ with different scaling coefficients. Regarding the
phase I, the APTES modified surface and short PEG chains (PEG245) behave similarly with
Mt growing with time following a square root relationship ( ) with α=23.10 and
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23.48 (R2=0.965 and 0.984 as from Table 2), respectively. For coating made with longer
PEG chains, the exponent β grows with the length of the polymer as listed in Tab. 2S, with β
ranging from 0.7 to 1.5; whereas α decreases leading to longer degradation times. Higher-
order degradation laws with Mt = αt3 have been observed for PEG3400 and PEG5000 with α
=0.0047 and α=0.0020, respectively with R2=0.999 in both cases as from Table 2 (Figure 4,
Table 2). For phase II, only particles coated with PEG3400 and PEG5000 exhibit a
significant degradation, whereas APTES modified and particles with short PEG chains (up
to PEG1214) have almost fully degraded after 18 hours. For PEG3400 and PEG5000, the
degradation law can be again described through a general power law of the type αtβ with
β=0.6 and α=6.87 (R2=0.971) and α=5.50 (R2=0.992), respectively.
Interestingly, for APTES modified and PEG245 coated particles, the degradation laws
exhibit a square root behavior which is possibly associated with a diffusive release of silicic
acid from the porous silicon matrix into the surrounding solution. As the length of the PEG
chains attached on the particle surface increases, the diffusion of the silicic acid from the
pores, where most of the degradation occurs, to the surrounding media is more and more
hindered possibly by surface steric interactions with the polymer chains. Notably, a similar
behavior is observed for PEG3400 and PEG5000 during phase II, with degradation laws
exhibiting an exponent β=0.6, which is very close to that associated with pure diffusion
(β=0.5). This would suggest that, during phase II, most of the PEG chains decorating the
particle surface have been removed and released in the surrounding medium because of the
degradation of the first porous layers.
The deterioration of the pSi microparticle surface morphology over time was evaluated by
Scanning Electron Microscopy (SEM). Figure 5 presents SEM micrographs of the particles
during the degradation process. The rate of deterioration of the microparticles was
associated with the rate of Si chemical degradation, and microparticles conjugated to higher
molecular weight PEGs exhibited surface deterioration at a much slower rate. It can be seen
that the degradation of the APTES modified (non-PEGylated) particles over time occurred
by means of erosion of the particles surface as well as of the pores. As the study progressed,
the pore sizes became wider and the surface of the particle less smooth and more irregular.
This degradation profile is in general agreement with the published reports on degradation of
porous silicon structures [10]. With intermediate PEG (MW 861), the appearance of the
particles during the in vitro degradation process changed. The most prominent erosion is
seen in the pores in comparison to the particle’s outer surface. This different degradation
pattern could be attributed to the steric hindrance of the hydrophilic polymer molecules
which probably cover particle surface more efficiently outside the pores, thus preventing
penetration of water and other components, which play an important role in the degradation
process. In the case of high MW PEG (5000) almost no degradation is seen within the first
48 hours, which confirms the data obtained by ICP-AES analysis.
To evaluate the kinetics of surface degradation of the particles, APTES and PEG3400
particles were labeled with the Dylight 488 fluorescent probe. The release kinetics of the
probe from particles surface into the degradation media was followed by fluorescence
intensity and FACS. Based on the fluoremetric analysis, for non-PEGylated particles, the
fluorescent probe conjugated to the surface was released into the degradation medium within
8–16 hours depending on the degradation medium. For PEGylated particles the surface
erosion rate was significantly extended and the fluorescent probe was released from the
particle surface only after 24–48 hours (Figure 6) as was also confirmed by FACS analysis
(data not shown). The obtained profiles were in agreement with the data on degradation
kinetics of the particles surface as evaluated by ICP-AES and SEM.
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The ability to control the release of drug and imaging agents from pharmaceutical systems is
critical for many clinical applications. In the case of the multistage delivery carrier 7,16–17
comprised of 1st stage microparticles bearing 2nd stage nanoparticles within the pores of pSi,
the release of the second stage nanoparticles from the 1st stage pSi microparticles will
depend on several mechanisms, including their diffusion outside the pores, as well as on the
simultaneous Si erosion and degradation of the matrix. The mechanism of degradation and
drug release from biodegradable controlled release systems can generally be described in
terms of three basic parameters. First, the type of the hydrolytically unstable linkage in the
system and its position. Second, the way the system biodegrades, either at the surface or
uniformly throughout the matrix, affects device performance substantially. The third
significant factor is the design of the drug delivery system encountering for system geometry
and morphology as well as for the mechanism of loading of therapeutic agents. For example,
the active agent may be covalently attached to the particle matrix and released as the bond
between drug and polymer cleaves.
The size and number of pores in pSi affects its physiochemical properties, and as a
consequence different types of mesoporous Si particles degrade in aqueous solutions and
biological fluids at different rates, which could be directly translated to release of free drugs
or second stage microparticles from the matrix. The pores of the particles could be
considered as a void fraction, being in constant contact with the degradation fluids and
presumably originating the orthosilicic acid - the degradation product of porous silicon.
Orthosilicic acid, Si(OH)4, is the biologically relevant water soluble form of silicon (Si),
recently proven to be play a significant role in bone and collagen growth. Porous Si films
release Si(OH)4 (silicic acid) in aqueous solutions in the physiological pH range through
hydrolysis of the Si-O bonds, 18 which is harmlessly excreted in the urine through the
kidneys 19. In this study we addressed the question how the surface modification of pSi
surface with PEG affect the degradation kinetics. APTES particles are a subject of
homogenous surface degradation, where the erosion occurs homogeneously throughout the
whole surface of the particle as well as the pores. In the case of PEGylated Si particles, the
obtained degradation profile could be defined as heterogeneous erosion which besides the
surface area, geometry and morphology of the particles is also defined by the length of the
polymer chains covering the particle surface. PEGylation in this case appears to be the factor
which controls penetration of solutes into the Si matrix of the particles. Derivatization can
dramatically affect light-emitting properties of pSi and is degradation. For example, Buriak
and co-workers have demonstrated that hydrosilyation with 1-dodecyne may sufficiently
stabilize the material to render it corrosion-resistant 20. It is also noteworthy that the higher
degradation rates are observed for the particles incubated with serum as compared to PBS,
indicating the stronger ionic strength or involvement of some biological processes such as
enzymatic degradation.
Events that follow the administration of foreign material into the body could provoke acute
or chronic inflammation, while the last one is characterized by the presence of macrophages
and release of inflammatory cytokines. Injectable biomaterials are expected to be
biocompatible in terms of lack of immunogenic and inflammatory responses. Though silicon
has been recognized as an essential trace element in the body which participates in
connective tissue, especially cartilage and bone formation 19, some forms of crystalline
silicon dioxide are known as a cytotoxic agent in macrophages 21–23. Thus, it was important
to assess the effect of pSi microparticles with various surface modifications on human
immune cells. Keeping this in mind, we evaluated the biocompatibility of the systems with
human monocyte derived differentiated cultured macrophages. Data clearly demonstrate that
the tested systems did not induce release of proinflammatory cytokines IL-6 and IL-8 over
48 hours period time in THP-1 macrophages (Figure 7). On contrary, when the cells were
incubated with zymosan particles, a positive control, a very prominent increase in the
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cytokines release was observed. Phagocytic receptors on macrophages bind zymosan,
stimulate particles engulfment and cytokines release. This agent is well known to induce
inflammatory signals in macrophages through toll-like receptors TLR2 and TLR6. These
results are in agreement with previously published studies on zymosan and other Si based
systems. As an example, silica based Sol-gel glass was reported not to induce a significant
inflammatory response by polymorphonuclear leukocytes 24 and oxidized nanoporous
silicon was found to be compatible with primary hepatocytes 25–26. In our recent study, we
have also shown that vascular endothelial cells, following internalization of silicon
microparticles, maintain cellular integrity, viability and normal mitotic division 17. More
explicit biocompatibility studies of the pSi microparticles for biomedical applications are
currently underway in various in vitro and in vivo models in our laboratory.
CONCLUSIONS
A fine control of the degradation and release kinetics of mesoporous silicon structures is of
fundamental importance in the development of multistage and multifunctional delivery
systems. pSi microcarriers can be administered systemically and used to deliver the payload
of different nature (therapeutic, imaging and so on). The size of the pores and the surface
chemistry of the pSi structure can be controlled during the fabrication process and thereafter.
We found that by conjugation of PEGs with various backbone length to porosified silicon
microparticles, it is possible to finely tune the degradation kinetics of the material
possessing large pores size. The most dramatic effect was observed for PEGs 3400 and 5000
which inhibited the degradation of the systems over more than 3 days. These data point
toward the possibility to control degradation of mesoporous silicon microparticles and
devices by means of PEGylation and may have important clinical implications.
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Figure 1.
Schematic presentation of chemical modification of pSi microparticles with APTES and
PEG molecules.
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Figure 2.
Degradation kinetics of large pores (pores size 30–50nm) and small pores (10nm) Si
microparticles as evaluated by ICP-AES. The degradation kinetic profile is expressed as a
percentage of the total Si contents released to the degradation medium.
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Figure 3.
Degradation kinetics of large pores PEGylated pSi microparticles as evaluated by ICP-AES.
The degradation kinetic profile is expressed as a percentage of the total Si contents released
to the degradation medium: (A) PBS pH 7.2; (B) Fetal Bovine Serum (FBS).
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Figure 4.
Comparison between the experimental data (dots) and the best fitting power laws αtβ for the
first phase of the degradation process according to scaling low Mt =α·tβ
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Figure 5.
SEM images of the pSi particles during the degradation process in PBS pH 7.2. Systems
shown: a) APTES particles; b) Particles modified with PEG 861; c) Particles modified with
PEG 5000. Timepoints: 2, 8, 18 and 48 hours.
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Figure 6.
Erosion of fluorescent PEG vs low MW probe from the pSi particle surface as followed up
by fluorimetry in the degradation medium in PBS and FBS. The degradation kinetic profile
is expressed as a percentage of the total fluorescence released to the degradation medium at
72 hours.
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Figure 7.
Release of proinflammatry cytokines IL-6 and IL-8 by human cultured THP-1 macrophages
following incubation with pSi particles with various surface modifications.
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Table 1
Description and zeta potential values of the investigated microparticles
Sample name Particles zeta potential, mV Mean ± SD (n=4)
Oxidized −31.05±2.73
APTES +14.73±1.62
PEG 245 −15.58±3.58
PEG 333 −3.69±2.23
PEG 509 −9.68±2.49
PEG 686 −13.44±3.40
PEG 862 −3.94±1.91
PEG 1214 −11.29±1.93
PEG 3400-Dylight 488 −8.34±2.51
PEG 5000 −6.48±2.84
Dylight 488 −15.44±3.40
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Table 2
Power law coefficients and R2 values for the first degradation phase.
Scaling coefficients R2
APTES α = 23.10 β = 0.5 0.965
PEG 245 α = 23.48 β = 0.5 0.984
PEG 333 α = 11.81 β = 0.7 0.999
PEG 509 α = 7.03 β = 0.9 0.994
PEG 686 α = 2.02 β = 1.3 0.986
PEG 862 α =1.46 β = 1.4 0.986
PEG 1214 α = 0.94 β = 1.5 0.998
PEG 3400 α = 0.0047 β = 3.5 0.999
PEG 5000 α = 0.0020 β = 3.0 0.999
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